Translational Research in Cancer Genetics: The Road Less Traveled
Translational Research in Cancer Genetics: The Road Less Traveled
复制标题
DOI：
10.1159/000272897
复制
发表时间：
2011-01-01
影响因子：
1.7
通讯作者：
Khoury, M. J.
中科院分区：
文献类型：
--
作者：
Schully, S. D.;Benedicto, C. B.;Khoury, M. J.
癌症基因的发现具有临床和公共卫生应用的潜力。为了利用这些发现，需要一个转化研究议程，将这些发现从实验室带到人群健康影响中。为了评估癌症遗传学转化研究的现状，我们分析了2007财政年度美国国家癌症研究所（NCI）的校外资助组合，以及2007年发表的癌症遗传学研究文章。我们将资助的赠款和出版物分类如下：T0为发现研究; T1为开发候选健康应用程序的研究（e.例如，在一个实施例中，测试或治疗）; T2是评估候选应用程序并制定循证建议的研究; T3是评估如何将循证建议纳入癌症护理和预防的研究; T4是评估健康结果和人口影响的研究。我们发现，1.8%的资助组合和0.6%的已发表文献是T2研究或以上。除了癌症遗传学的发现研究外，迫切需要一个转化研究基础设施，以系统地评估和转化癌症护理和预防的基因发现。版权所有（C）2009 S. Karger AG，巴塞尔
Gene discoveries in cancer have the potential for clinical and public health applications. To take advantage of such discoveries, a translational research agenda is needed to take discoveries from the bench to population health impact. To assess the current status of translational research in cancer genetics, we analyzed the extramural grant portfolio of the National Cancer Institute (NCI) from Fiscal Year 2007, as well as the cancer genetic research articles published in 2007. We classified both funded grants and publications as follows: T0 as discovery research; T1 as research to develop a candidate health application (e. g., test or therapy); T2 as research that evaluates a candidate application and develops evidence-based recommendations; T3 as research that assesses how to integrate an evidence-based recommendation into cancer care and prevention; and T4 as research that assesses health outcomes and population impact. We found that 1.8% of the grant portfolio and 0.6% of the published literature was T2 research or beyond. In addition to discovery research in cancer genetics, a translational research infrastructure is urgently needed to methodically evaluate and translate gene discoveries for cancer care and prevention. Copyright (C) 2009 S. Karger AG, Basel